Syndax Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated March 3, 2025, reports on Syndax Pharmaceuticals, Inc. (SNDX). The filing primarily serves to announce financial results for the quarter and full year ended December 31, 2024, via a press release furnished as Exhibit 99.1. Additionally, the company reported a change in its principal executive offices effective March 1, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release (Exhibit 99.1) referenced in Item 2.02 but are not detailed in the body of this 8-K document.
Material Changes
- Headquarters Relocation: Effective March 1, 2025, the company moved its headquarters from Waltham, MA, to 730 Third Avenue, Floor 9, New York, NY 10017.
- Contact Information: The company's telephone number remains unchanged at (781) 419-1400.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors within the text provided. Investors are directed to the press release (Exhibit 99.1) for details regarding the financial results for the period ended December 31, 2024. The filing includes standard disclaimers that the information in Item 2.02 is furnished and not deemed "filed" under Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Press Release) for specific financial figures for Q4 and FY 2024, as they are not listed in this summary document.
- Confirm the new headquarters address in New York, NY, for future correspondence.
- Verify the trading symbol (SNDX) on The Nasdaq Stock Market LLC.